The FDA approved acalabrutinib plus venetoclax for previously untreated CLL/SLL based on phase 3 AMPLIFY data. The fixed 14-month regimen improved progression-free survival versus chemotherapy.
The cell surface markers detection market is projected to grow from $7.01 billion in 2026 to $13.33 billion by 2034, driven by increasing adoption of flow cytometry and applications in immunotherapy research. The market serves pharmaceutical, biotechnology, academic, and clinical research organizations through various workflow stages including sample preparation and cell analysis.
CD28 and CD38 have been identified as new therapeutic targets for peripheral T-cell lymphomas, with a trispecific antibody showing in vitro efficacy. The targets are expressed in 57% and 42% of PTCL cases respectively, covering most entities. Separately, low CD38 expression on circulating tumor-reactive T cells predicts better response to immune checkpoint inhibitors in lung cancer.
